Cambridge Healthtech Institute's Fourth Annual

Characterization of Biotherapeutics

( 生物学疗法的特性评估 )

Improving Prediction, Screening and Characterization of New Biologic

2018年1月8日 - 9日

 

New biotherapeutics formats are flooding the discovery and development pipelines and with this comes an increasing need for better and faster characterization tools and strategies, improved biomolecular and biophysical assays for the new biotherapeutics. The Fourth Annual Characterization of Biotherapeutics conference will present new tools, strategies and case studies on analytical development and characterization of mAbs, ADCs, bispecifics, and other novel protein formats, biosimilars, HOS, and developability. We are looking for cutting edge tools, research findings and unpublished data to be featured at this forum.

We invite you to submit a proposal, present a poster and attend to join with colleagues in this discussion of the key challenges and solutions improving predication, screening and characterization of new biologics.

We invite presentation proposals on the following preliminary topics:

  • Developability and analytical characterization, new assays and novel tools for characterization of antibody-drug conjugates (ADCs), bispecifics, multi-specifics, oligos, new protein formats and new viral therapeutics
  • Characterization of conjugation: Linker characterization, payload, biophysical testing for binding affinity
  • Biophysical characterization and property based molecular design
  • Physico-chemical method for the prediction of bioactivity, high throughput immunoassay and biochemical assay
  • Characterization of biodistribution and in vivo fate of biologics: Case studies on correlation between in vitro and in vivo findings
  • Higher order structure (HOS) characterization in biologics and structure, function and stability relationship
  • Application of mass spectroscopy for characterization
  • Biosimilars and analytical comparability
  • Characterization of process impurities, product variants, post translational modifications for new biologics and mAbs
  • New tools for sequence variance analysis and multi-attribute analysis
  • New developments in high throughput assays, automation, in line assays and miniaturized assay

* 活动内容有可能不事先告知作更动及调整。